Welcome to our dedicated page for Acadia Pharmaceuticals SEC filings (Ticker: ACAD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents help investors understand how Acadia reports its financial results, material events, and governance changes as it develops and commercializes medicines for neurological and rare diseases.
Acadia’s current reports on Form 8‑K include items such as quarterly and year‑to‑date financial results and updates on board composition. For example, the company has filed 8‑Ks to furnish press releases announcing results for the three and nine months ended September 30, 2025, and for the three and six months ended June 30, 2025, under Item 2.02 (Results of Operations and Financial Condition. Another 8‑K discloses the resignation of a member of the Board of Directors under Item 5.02, noting that the resignation was not due to any dispute or disagreement with the company or the Board.
In addition to 8‑Ks, Acadia files annual and quarterly reports that typically contain detailed discussions of its commercial portfolio, including NUPLAZID for hallucinations and delusions associated with Parkinson’s disease psychosis and DAYBUE for Rett syndrome, as well as information on its pipeline programs in Alzheimer’s disease psychosis, Lewy body dementia psychosis, essential tremor, and other neuroscience and neuro‑rare indications. These filings generally address revenue composition, research and development spending, risk factors, and other information relevant to ACAD shareholders.
On Stock Titan, Acadia’s SEC filings are supplemented with AI-powered summaries that explain the key points of lengthy documents such as 10‑K annual reports, 10‑Q quarterly reports, and 8‑K current reports in plain language. Real-time updates from the SEC’s EDGAR system help users see new filings as they appear, while AI analysis highlights important changes in financial metrics, business priorities, and risk disclosures. Investors can also review insider-related filings such as Form 4 to monitor transactions by directors and officers in ACAD stock.
By combining original SEC documents with automated explanations, this filings page helps users quickly identify what Acadia is reporting about its financial condition, commercial performance, and development programs in neurological and rare diseases.